Natural killer cells in rheumatoid arthritis patients were reduced upon IFX therapy [44] and in ulcerative colitis patients derived cells, IFX treatment decreased the proliferation of CD4+ and CD8+ T-cells as well as their secretion level of IFNγ and TNFα, among other cytokines [45]. The gene discussed is CD4; the disease is rheumatoid arthritis.